Value in Health: Defining a Core Data Set for the Economic Evaluation of Precision Oncology
Despite the growing abundance of multiomic data in precision oncology, the lack of standardization and interoperability impedes economic evaluation. In the latest issue of Value in Health, Samantha Pollard, PhD et al. found significant variability in published data resources. Through their work, they identified a core set of 68 data elements that they believe would support accurate and efficient economic evaluations.
Contract research organization Service Market Trends, Leading Key Players, Future Growth, Revenue, Demand Forecast, Applications 2021-2027
A comprehensive overview of the contract research organization services market is recently added by UnivDatos Market Insights to its humongous [...]
Politico Analysis: Health Data Breaches Accelerated in 2021
Health data breaches have surged by 300% in the past three years, with almost 50 million Americans having their [...]
Value-Based Healthcare Services Market Report for 2022-2029
A2Z Market Research has released a new report detailing its projections for the worldwide value-based healthcare services market. This report [...]
White Paper: Model-Based Approach for Better Enrollment Forecasting
According to the Clinical Trials Database, low recruitment rates were the largest factor determining whether a trial would terminate in [...]
Systemic Review: Real-World Data for Healthcare Research in China
Despite the emergence of several new sources of real-world evidence for healthcare in China, little has been done to evaluate [...]
Infographic – By the Numbers: National Health Insurance Marketplace Dec ‘21
AIS Health, an MMIT company, has released a new infographic detailing the landscape of the US health insurance marketplace in [...]
2022 Health Trends Report Released by Syneos Health
Syneos Health has just released their 2022 Health Trends: Insights for Industry Change Agents report. The key trends for the [...]
Cytel Blog Discusses Whether Promising Zone Design is Optimal
Jennison and Turnbull developed promising zone design in 2015 to help determine initial sample sizes for early clinical trials that [...]
Q3 2021 Health Plan Enrollment Data
In the latest update to the Directory of Health Plans, MMIT’s AIS Health has released health plan enrollment data for [...]
COVID-19 Data Destruction Investigation Begins at the University of Florida
Following several complaints that University of Florida faculty members were pressured to delay or destroy COVID-19 research data, the university [...]
Webinar: Adaptive Sample Size Reassessment – Conditional Powers or Bayesian Predictive Power?
Cytel’s Executive Research Principal, Rajat Mukherjee discusses using a Bayesian Predictive Power (PP) calculation for Adaptive Sample Size [...]
75% of Insured Americans Worry About Medical Bills – Women Disproportionately Impacted
According to the recent MITRE Insurance Survey, 75% of insured Americans are worried about financial issues due to medical bills. [...]
Now Available: Economic & Related Consulting Service Revenues WORLD REPORT + DATABASE
Research and Markets has released their Economic & Related Consulting Service Revenues World Report + Database, which covers products and [...]
Machine Learning to Predict Reentry Rates Using Hospital RWE
Machine learning, an advanced automated data analysis method, may predict 30-day hospital readmission rates, according to a report published [...]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic [...]
HealthVerity’s IPGE RWD Platform Ensures Privacy
The HealthVerity Identity, Privacy, Governance and Exchange (IPGE) Platform offers useable real world data (RWD). The platform was created in [...]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and [...]
Certara Leaders Discuss Leveraging RWD to Advance R&D and Meet Global Payers’ Needs
Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet [...]
Upcoming December Webinar on RWE in Pharma Featuring Leaders at IQVIA, Roche, and Janssen
The Evidence Base will host a webinar on real world evidence (RWE) in pharma at 7:00 AM on December 8th, [...]
CEVR Director Publishes Article on Improving Data Dashboards for Drug Value Assessments
Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center Peter Neumann [...]
Obesity Journal Editor Cashes In on Weight-Loss Drug Research; $1.2 Million Raises Ethical Questions
Associate Editor-in-Chief of the journal Obesity Donna Ryan is facing scrutiny following revelations that she received substantial sums from pharma, [...]
Roche Turns to RWE in Lung Cancer Study
Roche turned to real world evidence (RWE) to understand how a subgroup of patients with an anaplastic lymphoma kinase translocation (ALK) [...]
Cost-Effectiveness Analyses Fail to Consider Health Equity
Although an important tool in assessing a drug’s value, cost-effectiveness analyses (CEAs) fail to account for health equity. Important information [...]
xCures Seeks to Improve Patient Outcomes Using Targeted Oncology RWD
xCures aims to improve the outcomes of patients with cancer using real world data (RWD) tools. Quickly identifying relevant patient [...]
